Camden National Bank Invests $241,000 in Hologic, Inc. (NASDAQ:HOLX)

Camden National Bank bought a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,340 shares of the medical equipment provider’s stock, valued at approximately $241,000.

Several other hedge funds have also bought and sold shares of the stock. Benson Investment Management Company Inc. bought a new position in shares of Hologic in the fourth quarter worth about $4,832,000. Principal Financial Group Inc. raised its stake in Hologic by 0.6% during the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock worth $19,547,000 after acquiring an additional 1,606 shares during the period. Clean Yield Group lifted its holdings in Hologic by 18.9% during the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock valued at $3,291,000 after purchasing an additional 7,266 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Hologic by 2.9% during the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after purchasing an additional 800 shares in the last quarter. Finally, Versor Investments LP bought a new position in shares of Hologic in the third quarter worth approximately $1,677,000. Institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on HOLX. Royal Bank of Canada dropped their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating for the company in a report on Thursday, February 6th. Raymond James reaffirmed an “outperform” rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. William Blair reissued an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Leerink Partnrs downgraded Hologic from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 6th. Finally, Evercore ISI cut their price objective on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Performance

Hologic stock opened at $64.54 on Friday. The company’s 50-day moving average price is $68.35 and its 200-day moving average price is $75.46. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The company has a market cap of $14.48 billion, a PE ratio of 20.36, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a twelve month low of $61.70 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.